Table of Contents
Volume 99, Issue 9: September 2014

Cover Figure
Artistic impression of hematopoietic colonies in semi-solid medium.
(image created by www.somersault1824.com)

Editorials & Perspectives
1405  MLL5 expression as a biomarker for DNA hypermethylation and the sensitization of leukemia cells to epigenetic therapy
      Thomas A. Milne

1407  Treating advanced cardiac damage in light chain amyloidosis: still an unmet need
      Giampaolo Merlini et al.

Review Articles
1410  Survival analysis in hematologic malignancies: recommendations for clinicians
      Julio Delgado, et al.

1421  Early lymphoid lesions: conceptual, diagnostic and clinical challenges
      Karthik A. Ganapathi, et al.

Articles
Bone Marrow Failure
1433  In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia
      Xingmin Feng, et al

Chronic Myeloid Leukemia
1441  Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
      Benjamin Hanfstein, et al.

Myeloproliferative Disorders
1448  JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate
      Camilla Nielsen, et al.

Acute Myeloid Leukemia
1456  Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia
      Haiyang Yun, et al.

1465  Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction
      Angeliki Thanasopoulou, et al.

1472  The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international
      study Relapsed AML 2001/01
      Ursula Creutzig, et al.

Plasma Cell Disorders
1479  Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis
      (Mayo Clinic stage III)
      Arnaud Jaccard, et al.
Stem Cell Transplantation

1486 Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial
Patrice Chevallier, et al.

1492 Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT
Yves Chalandon, et al.

1499 Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation
Kazuyuki Murase, et al.

1509 Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen
Annalisa Ruggeri, et al.

Anemia of Chronic Disease

1516 Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats
Milan Theurl, et al.

Quality of Life

1525 Health-related quality of life in children with newly diagnosed immune thrombocytopenia
Katja M.J. Heitink-Pollé, et al.

Errata Corrige

1532 Molecular analysis of Fanconi anemia: the experience of the Bone Marrow Failure Study Group of the Italian Association of Pediatric Onco-Hematology
Daniela De Rocco, et al.

Letters to the Editor

Letters are available online only at www.haematologica.org/content/99/9.toc

e148 PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin
Sarah L. Ondrejka, et al.
http://www.haematologica.org/content/99/9/e148

e152 SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms
Emiliano Fabiani, et al.
http://www.haematologica.org/content/99/9/e152

e154 Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma
Fatima Hamadeh, et al.
http://www.haematologica.org/content/99/9/e154

e156 A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy
Diane M.T. Hanna, et al.
http://www.haematologica.org/content/99/9/e156

e159 Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients
Marco Montillo, et al.
http://www.haematologica.org/content/99/9/e159
e162  Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
   Dominik Dytkfeld, et al.
   http://www.haematologica.org/content/99/9/e162

e165  Genetic characterization of acquired aplastic anemia by targeted sequencing
   Michael Heuser, et al.
   http://www.haematologica.org/content/99/9/e165

e168  Severe nondominant hereditary spherocytosis due to uniparental isodisomy at the SPTA1 locus
   Hannah Bogardus et al.
   http://www.haematologica.org/content/99/9/e168

e171  Hematologic parameters predicting a response to oral iron therapy in chronic inflammation
   Susanne van Santen, et al.
   http://www.haematologica.org/content/99/9/e171

e174  Remission status should not be treated as a base-line covariate – Reply to Etienne et al.
   Michael Lauseker, et al.
   http://www.haematologica.org/content/99/9/e174